Neumora Therapeutics Inc. has outlined its 2026 pipeline strategy, which includes several key initiatives and upcoming milestones. The company plans to conduct a joint topline data readout for the KOASTAL-2 and KOASTAL-3 studies of navacaprant in major depressive disorder in the second quarter of 2026, with increased enrollment targets for both studies. Neumora also intends to initiate a clinical program in the first half of 2026 to evaluate NMRA-215 as both a monotherapy and in combination therapy for the treatment of obesity, with weight loss data expected by the end of 2026. Additionally, the company is advancing the development of NMRA-511 following favorable Phase 1b results. Neumora reports that its cash, cash equivalents, and marketable securities are expected to support operations into the third quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9619497) on January 05, 2026, and is solely responsible for the information contained therein.